Cargando…

The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation

Much remains to be learned about the molecular mechanisms underlying a class of human disorders called actinopathies. These genetic disorders are characterized by loss-of-function mutations in actin-associated proteins that affect immune cells, leading to human immunopathology. However, much remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Ronzier, Elsa, Laurenson, Alexander J., Manickam, Rohini, Liu, Sophia, Saintilma, Imelda M., Schrock, Dillon C., Hammer, John A., Rotty, Jeremy D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9180445/
https://www.ncbi.nlm.nih.gov/pubmed/35681501
http://dx.doi.org/10.3390/cells11111806
_version_ 1784723519977816064
author Ronzier, Elsa
Laurenson, Alexander J.
Manickam, Rohini
Liu, Sophia
Saintilma, Imelda M.
Schrock, Dillon C.
Hammer, John A.
Rotty, Jeremy D.
author_facet Ronzier, Elsa
Laurenson, Alexander J.
Manickam, Rohini
Liu, Sophia
Saintilma, Imelda M.
Schrock, Dillon C.
Hammer, John A.
Rotty, Jeremy D.
author_sort Ronzier, Elsa
collection PubMed
description Much remains to be learned about the molecular mechanisms underlying a class of human disorders called actinopathies. These genetic disorders are characterized by loss-of-function mutations in actin-associated proteins that affect immune cells, leading to human immunopathology. However, much remains to be learned about how cytoskeletal dysregulation promotes immunological dysfunction. The current study reveals that the macrophage actin cytoskeleton responds to LPS/IFNγ stimulation in a biphasic manner that involves cellular contraction followed by cellular spreading. Myosin II inhibition by blebbistatin blocks the initial contraction phase and lowers iNOS protein levels and nitric oxide secretion. Conversely, conditional deletion of Arp2/3 complex in macrophages attenuates spreading and increases nitric oxide secretion. However, iNOS transcription is not altered by loss of myosin II or Arp2/3 function, suggesting post-transcriptional regulation of iNOS by the cytoskeleton. Consistent with this idea, proteasome inhibition reverses the effects of blebbistatin and rescues iNOS protein levels. Arp2/3-deficient macrophages demonstrate two additional phenotypes: defective MHCII surface localization, and depressed secretion of the T cell chemokine CCL22. These data suggest that interplay between myosin II and Arp2/3 influences macrophage activity, and potentially impacts adaptive-innate immune coordination. Disrupting this balance could have detrimental impacts, particularly in the context of Arp2/3-associated actinopathies.
format Online
Article
Text
id pubmed-9180445
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91804452022-06-10 The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation Ronzier, Elsa Laurenson, Alexander J. Manickam, Rohini Liu, Sophia Saintilma, Imelda M. Schrock, Dillon C. Hammer, John A. Rotty, Jeremy D. Cells Article Much remains to be learned about the molecular mechanisms underlying a class of human disorders called actinopathies. These genetic disorders are characterized by loss-of-function mutations in actin-associated proteins that affect immune cells, leading to human immunopathology. However, much remains to be learned about how cytoskeletal dysregulation promotes immunological dysfunction. The current study reveals that the macrophage actin cytoskeleton responds to LPS/IFNγ stimulation in a biphasic manner that involves cellular contraction followed by cellular spreading. Myosin II inhibition by blebbistatin blocks the initial contraction phase and lowers iNOS protein levels and nitric oxide secretion. Conversely, conditional deletion of Arp2/3 complex in macrophages attenuates spreading and increases nitric oxide secretion. However, iNOS transcription is not altered by loss of myosin II or Arp2/3 function, suggesting post-transcriptional regulation of iNOS by the cytoskeleton. Consistent with this idea, proteasome inhibition reverses the effects of blebbistatin and rescues iNOS protein levels. Arp2/3-deficient macrophages demonstrate two additional phenotypes: defective MHCII surface localization, and depressed secretion of the T cell chemokine CCL22. These data suggest that interplay between myosin II and Arp2/3 influences macrophage activity, and potentially impacts adaptive-innate immune coordination. Disrupting this balance could have detrimental impacts, particularly in the context of Arp2/3-associated actinopathies. MDPI 2022-05-31 /pmc/articles/PMC9180445/ /pubmed/35681501 http://dx.doi.org/10.3390/cells11111806 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ronzier, Elsa
Laurenson, Alexander J.
Manickam, Rohini
Liu, Sophia
Saintilma, Imelda M.
Schrock, Dillon C.
Hammer, John A.
Rotty, Jeremy D.
The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation
title The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation
title_full The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation
title_fullStr The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation
title_full_unstemmed The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation
title_short The Actin Cytoskeleton Responds to Inflammatory Cues and Alters Macrophage Activation
title_sort actin cytoskeleton responds to inflammatory cues and alters macrophage activation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9180445/
https://www.ncbi.nlm.nih.gov/pubmed/35681501
http://dx.doi.org/10.3390/cells11111806
work_keys_str_mv AT ronzierelsa theactincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT laurensonalexanderj theactincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT manickamrohini theactincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT liusophia theactincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT saintilmaimeldam theactincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT schrockdillonc theactincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT hammerjohna theactincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT rottyjeremyd theactincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT ronzierelsa actincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT laurensonalexanderj actincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT manickamrohini actincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT liusophia actincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT saintilmaimeldam actincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT schrockdillonc actincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT hammerjohna actincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation
AT rottyjeremyd actincytoskeletonrespondstoinflammatorycuesandaltersmacrophageactivation